Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8SU6N)

Drug Name
LY-2183240 Drug Info
Synonyms
LY2183240; 874902-19-9; LY 2183240; UNII-2WBU91OKM7; 2WBU91OKM7; CHEMBL509860; LY-2183240; 5-Biphenyl-4-ylmethyl-tetrazole-1-carboxylic acid dimethylamide; LY2183240/LY-2183240; 1H-Tetrazole-1-carboxamide, 5-([1,1'-biphenyl]-4-ylmethyl)-N,N-dimethyl-; 1H-Tetrazole-1-carboxamide, 5-((1,1'-biphenyl)-4-ylmethyl)-N,N-dimethyl-; SCHEMBL2184828; CTK8E8366; CHEBI:92670; KS-00001CUG; BDBM26736; AOB2582; MolPort-023-219-146; HMS3269E15; BCP22610; ZINC13813297; MFCD08703123; 3796AH; AKOS024457108; CS-0913; BCP9000870; LP01268; NCGC00159571-01
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11507802
ChEBI ID
CHEBI:92670
CAS Number
CAS 874902-19-9
TTD Drug ID
DM8SU6N

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Fatty acid amide hydrolase (FAAH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [2]
Thiopental DMGP8AX Anaesthesia 9A78.6 Approved [3]
JNJ-42165279 DM72GZO Anxiety disorder 6B00-6B0Z Phase 2 [4]
SSR411298 DMGTB2Q Major depressive disorder 6A70.3 Phase 2 [5]
IW-6118 DMP42W1 Inflammation 1A00-CA43.1 Phase 2 [6]
PF-04457845 DMPRYU1 Liver disease DB90-BD99 Phase 2 [7]
IPI-940 DMEIM5G Pain MG30-MG3Z Phase 1 [8]
PMID29053063-Compound-11d DMDRK68 N. A. N. A. Patented [9]
Piperazine carbamic compound 1 DMZSYU4 N. A. N. A. Patented [9]
Piperazine carbamic compound 2 DMMQ0ZO N. A. N. A. Patented [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fatty acid amide hydrolase (FAAH) TTDP1UC NOUNIPROTAC Inhibitor [1]

References

1 Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors. J Med Chem. 2008 Dec 11;51(23):7327-43.
2 Glutamate- and GABA-based CNS therapeutics. Curr Opin Pharmacol. 2006 Feb;6(1):7-17.
3 The general anesthetic propofol increases brain N-arachidonylethanolamine (anandamide) content and inhibits fatty acid amide hydrolase. Br J Pharmacol. 2003 Jul;139(5):1005-13.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
6 The Discovery and Development of Inhibitors of Fatty Acid Amide Hydrolase (FAAH). Bioorg Med Chem Lett. 2011 August 15; 21(16): 4674-4685.
7 Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett. 2011 Feb 10;2(2):91-96.
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1400).
9 A patent review of Monoacylglycerol Lipase (MAGL) inhibitors (2013-2017).Expert Opin Ther Pat. 2017 Dec;27(12):1341-1351.